A Prospective Randomized Pilot Study Using Ice Chips Versus Room Temperature Normal Saline Rinses Orally During Administration of Melphalan to Decrease the Severity and Duration of Oral Mucositis in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplant
- Compare the efficacy of administering ice chips vs room temperature normal saline oral
rinse before, during, and after melphalan administration, in terms of reducing or
eliminating grade 3 or 4 oral mucositis, in patients undergoing autologous peripheral
blood stem cell transplantation (PBSCT) for multiple myeloma.
- Compare the number of days that IV narcotic therapy is required for oral mucositis pain
in patients treated with these regimens.
- Compare the use of IV hydration and/or total parenteral nutrition after autologous
PBSCT in patients treated with these regimens.
- Compare overall quality of life, in terms of ability to eat food and drink liquids, in
patients treated with these regimens.
OUTLINE: This is a randomized, pilot study. Patients are stratified according to age (less
than 60 years vs 60 years and over). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral ice chips 15 minutes before, during, and for 8 hours after
melphalan infusion* on day -2.
- Arm II: Patients receive room temperature normal saline oral rinses over 30 seconds 15
minutes before, during, and for 8 hours after melphalan infusion* on day -2.
All patients undergo autologous peripheral blood stem cell transplantation (PBSCT)* on day
NOTE: *Patients receive melphalan infusion and undergo autologous PBSCT on protocol
Quality of life is assessed 3 days a week for 4 weeks.
After completion of study treatment, patients are followed for 28 days and then periodically
PROJECTED ACCRUAL: A total of 40 patients (20 per treatment arm) will be accrued for this
study within 18 months.
Primary Purpose: Supportive Care
William I. Bensinger, MD
Fred Hutchinson Cancer Research Center
United States: Federal Government
|Fred Hutchinson Cancer Research Center||Seattle, Washington 98109|